Finally was able to read the transcript after not succeeding yesterday. Where I'm at on vacation this week has weak internet. Will be reading your reference when I get back next week. As you say, it doesn't feel like their will be a pozi abstract at ASCO but w the caveat that prior to this last week, Spectrum management wasn't saying anything about a AACR abstract either so there's that. If it's either presenting at ASCO or WCLC, it would have to be WCLC where the data will be 3 or so months more mature but if they are allowed to present interim EGFR and HER2 data at ASCO in June and more mature interim data at WCLC in Sept then that's a possibility. I don't think SPPI can make any stronger comments than what they are making w/o irritating MDACC. I think you can present more mature data at a follow-up conference but I remember Adam F making a big stink about another biotech doing that several years ago with that biotech having to remove their more mature data abstract from the conference. But after everything was said and done, I believe that the belief was that that biotech should have been able to present their mature data at that later conference. We'll see.
As an aside, I wish I had some spare money laying around to buy SPPI at this ~$4 discounted price and just sell it in 6 months later if you believe pozi will be a winner. This would be in addition to my L-T shares I have now. That would be an easy short-term trade and money I think. Now if that other biotech I own (cough, cough, wink, wink) would just sky rocket, I would sell some of that and buy SPPI for a 6 month trade (or keep for a longer opportunity) but looks like I'll be sitting on the sidelines regarding this opportunity. SPPI looks much stronger now that they strengthened their balance sheet and don't have the Sword of Damacles hanging over their head with the convertable due at the end of the year.
